Impact of antimicrobial therapy on the gut microbiome

Journal of Antimicrobial Chemotherapy

Volumn 74, Issue , 2019, Pages I6-I15

  Bhalodi, Amira A ^a   Van Engelen, Tjitske S R ^b   Virk, Harjeet S ^b   Wiersinga, W Joost ^b  

^a Accelerate Diagnostics Inc   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; COMMENSAL; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; FAECALIBACTERIUM; FECES MICROFLORA; HUMAN; INTESTINE FLORA; NEWBORN SEPSIS; PSEUDOMONAS AERUGINOSA; SEPSIS; ANIMAL; BACTERIUM; DRUG EFFECT; MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CRITICAL ILLNESS; GASTROINTESTINAL MICROBIOME; HUMANS; MICE; SEPSIS;

EID: 85060637372     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky530     Document Type: Article

References (108)

1. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. NEngl JMed2016; 375: 2369-79.
2. McDonald D, Ackermann G, Khailova L et al. Extreme dysbiosis of the microbiome in critical illness. mSphere 2016; 4: e00199-16.
3. Marquet K, Liesenborgs A, Bergs J et al. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review andmeta-Analysis. Crit Care 2015; 19: 63.
4. Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive CareMed 2017; 43: 304-77.
5. Sullivan Å , Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of humanmicroflora. Lancet Infect Dis 2001; 1: 101-14.
6. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gutmicrobiota: between good and evil. Gut 2016; 65: 1906-15.
7. BlaserMJ. Antibiotic use and its consequences for the normal microbiome. Science 2016; 352: 544-5.
8. Stevens V, Dumyati G, Fine LS et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53: 42-8.
9. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013; 13: 790-801.
10. Tacconelli E, De Angelis G, Cataldo MA et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 2009; 53: 4264-9.
11. DiNubile MJ, Chow JW, Satishchandran V et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-Tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 2005; 49: 3217-21.
12. Baden LR, ThiemkeW, Skolnik A et al. Prolonged colonization with vancomycin-resistant Enterococcus faeciumin long-Termcare patients and the significance of "clearance". Clin Infect Dis 2001; 33: 1654-60.
13. Pamer EG. Resurrecting the intestinal microbiota to combat antibioticresistant pathogens. Science 2016; 352: 535-8.
14. Brandl K, Plitas G, Mihu CN et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008; 455: 804-7.
15. Malik U, Armstrong D, Ashworth M et al. Association between prior antibiotic therapy and subsequent risk of community-Acquired infections: a systematic review. J Antimicrob Chemother 2018; 73: 287-96.
16. Prescott HC, Dickson RP, Rogers MAM et al. Hospitalization type and subsequent severe sepsis.AmJ Respir Crit CareMed 2015; 192: 581-8.
17. Haak BW, Levi M, Wiersinga WJ. Microbiota-Targeted therapies on the intensivecareunit. Curr Opin Crit Care 2017; 23: 167-74.
18. Haak BW, Wiersinga WJ. The role of the gut microbiota in sepsis. Lancet Gastroenterol Hepatol 2017; 2: 135-43.
19. Maier L, Pruteanu M, Kuhn M et al. Extensive impact of non-Antibiotic drugs on human gut bacteria. Nature 2018; 555: 623-8.
20. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-10.
21. Lankelma JM, van Vught LA, Belzer C et al. Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study. IntensiveCareMed2017; 43: 59-68.
22. Zaborin A, Smith D, Garfield K et al. Membership and behavior of ultralow-diversity pathogen communities present in the gut of humans during prolonged critical illness. MBio 2014; 5: e01361-14.
23. Buelow E, Bello González TDJ, Fuentes S et al. Comparative gut microbiota and resistome profiling of intensive care patients receiving selective digestive tract decontamination and healthy subjects. Microbiome 2017; 5: 88.
24. Krezalek MA, DeFazio J, Zaborina O et al. The shift of an intestinal 'microbiome' to a 'pathobiome' governs the course and outcome of sepsis following surgical injury. Shock 2016; 45: 475-82.
25. Ojima M, Motooka D, Shimizu K et al. Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute phase of intensive care unit patients. Dig Dis Sci 2016; 61: 1628-34.
26. Hotterbeekx A, Xavier BB, Bielen K et al. The endotracheal tube microbiome associatedwith Pseudomonas aeruginosa or Staphylococcus epidermidis. Sci Rep 2016; 6: 36507.
27. Akrami K, Sweeney DA. The microbiome of the critically ill patient. Curr Opin Crit Care 2018; 24: 49-54.
28. YehA, RogersMB, Firek B et al. Dysbiosis across multiple body sites in critically ill adult surgical patients. Shock 2016; 46: 649-54.
29. WischmeyerPE, McDonaldD, Knight R. Roleof themicrobiome, probiotics, and 'dysbiosis therapy' in critical illness. Curr Opin Crit Care 2016; 22: 347-53.
30. Dickson RP. The microbiome and critical illness. Lancet Respir Med 2016; 4: 59-72.
31. Lankelma JM, Birnie E, Weehuizen TAF et al. The gut microbiota as a modulator of innate immunity during melioidosis. PLoS Negl Trop Dis 2017; 11: e0005548.
32. Deriu E, Boxx GM, He X et al. Influenza virus affects intestinal microbiota and secondary Salmonella infection in the gut through Type I interferons. PLoS Pathog 2016; 12: e1005572.
33. Winglee K, Eloe-Fadrosh E, Gupta S et al. AerosolMycobacteriumtuberculosis infection causes rapid loss of diversity in gut microbiota. PLoS One 2014; 9: e97048.
34. Arboleya S, Binetti A, Salazar N et al. Establishment and development of intestinal microbiota in preterm neonates. FEMS Microbiol Ecol 2012; 79: 763-72.
35. Holmes E, Loo RL, Stamler J et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008; 453: 396-400.
36. Smith MI, Yatsunenko T, Manary MJ et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013; 339: 548-54.
37. Stefka AT, Feehley T, Tripathi P et al. Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci USA 2014; 111: 13145-50.
38. Hsiao EY, McBride SW, Hsien S et al. Microbiotamodulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013; 155: 1451-63.
39. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 2016; 8: 39.
40. Almagor J, Temkin E, Benenson I et al. The impact of antibiotic use on transmission of resistant bacteria in hospitals: insights from an agent-based model. PLoS One 2018; 13: e0197111.
41. Graffunder EM, Preston KE, Evans AM et al. Risk factors associated with extended-spectrum b-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005; 56: 139-45.
42. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 2011; 159: 392-7.
43. GibsonMK, WangB, Ahmadi S et al. Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome. Nat Microbiol 2016; 1: 16024.
44. Seale JV, Hutchinson RA, Fleming PF et al. Does antibiotic choice for the treatment of suspected late-onset sepsis in premature infants determine the risk of developing necrotising enterocolitis? A systematic review. Early Hum Dev 2018; 123: 6-10.
45. Blaser M. Antibiotic overuse: stop the killing of beneficial bacteria. Nature 2011; 476: 393-4.
46. Vincent J-L, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
47. Roager HM, Hansen LBS, Bahl MI et al. Colonic transit time is related to bacterialmetabolismandmucosal turnover in the gut. Nat Microbiol 2016; 1: 16093.
48. Price R, MacLennan G, Glen J et al. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-Analysis. BMJ 2014; 348: g2197.
49. vanNoodE, VriezeA, NieuwdorpMet al. Duodenal infusion of donor feces for recurrent Clostridiumdifficile.NEngl JMed2013; 368: 407-15.
50. de Smet AMGA, Kluytmans JAJW, Blok HEM et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011; 11: 372-80.
51. WittekampBH, Plantinga NL, Cooper BS et al. Decontamination strategies and bloodstream infections with antibiotic-resistant microorganisms in ventilated patients: a randomized clinical trial. JAMA 2018; 320: 2087-98.
52. Hurley JC. Is selective decontamination of the digestive tract safe? Clin Infect Dis 2015; 60: 1729-30.
53. ManzanaresW, LemieuxM, Langlois PL et al. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-Analysis. Crit Care 2016; 19: 262.
54. Panigrahi P, Parida S, Nanda NC et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature 2017; 548: 407-12.
55. Moellering RC. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14 Suppl D: 43-52.
56. Nord CE, Brismar B, Kasholm-Tengve B et al. Effect of piperacillin/tazobactam treatment on human bowel microflora. J Antimicrob Chemother 1993; 31 Suppl A: 61-5.
57. Kundrapu S, Sunkesula VCK, Jury LA et al. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridiumdifficile reduce the risk for acquisition of C. difficile colonization? BMC Infect Dis 2016; 16: 159.
58. Kager L, Malmborg AS, Nord CE et al. The effect of piperacillin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Infection 1983; 11: 251-4.
59. Stiefel U, Pultz NJ, Helfand MS et al. Increased susceptibility to vancomycin-resistant Enterococcus intestinal colonization persists after completion of anti-Anaerobic antibiotic treatment in mice. Infect Control Hosp Epidemiol 2004; 25: 373-9.
60. Paterson DL, Muto CA, Ndirangu M et al. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-Tazobactam versus those receiving cefepimecontaining antibiotic regimens. Antimicrob Agents Chemother 2008; 52: 465-9.
61. Bächer K, Schaeffer M, Lode H et al. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother 1992; 30: 365-75.
62. Kemmerich B, Warns H, Lode H et al. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother 1983; 24: 333-8.
63. Knothe H, Dette GA, Shah PM. Impact of injectable cephalosporins on the gastrointestinal microflora: observations in healthy volunteers and hospitalized patients. Infection 1985; 13 Suppl 1: S129-33.
64. Flokas ME, Karageorgos SA, Detsis M et al. Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-Analysis. Int J Antimicrob Agents 2017; 49: 565-72.
65. Rice LB, Hutton-Thomas R, Lakticova V et al. b-Lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J Infect Dis 2004; 189: 1113-18.
66. McKinnell JA, Kunz DF, Moser SA et al. Patient-level analysis of incident vancomycin-resistant enterococci colonization and antibiotic days of therapy. Epidemiol Infect 2016; 144: 1748-55.
67. King ST, Barber KE, Parham JJ et al. Shifts in antimicrobial consumption and infection rates before and during a piperacillin/tazobactam shortage. J Glob Antimicrob Resist 2017; 11: 111-13.
68. Richards DM, Heel RC, Brogden RN et al. Ceftriaxone. A reviewof its antibacterial activity, pharmacological properties and therapeutic use. Drugs 1984; 27: 469-527.
69. Welling GW, Meijer-Severs GJ, Helmus G et al. The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract. Infection 1991; 19: 313-16.
70. de Vries-Hospers HG, Tonk RH, van der Waaij D. Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers. Scand J Infect Dis 1991; 23: 625-33.
71. Cavallaro V, Catania V, Bonaccorso R et al. Effect of a broad-spectrum cephalosporin on the oral and intestinal microflora in patients undergoing colorectal surgery. JChemother 1992; 4: 82-7.
72. Vogel F, Ochs HR, Wettich K et al. Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-Acquired pneumonia. Clin Microbiol Infect 2001; 7: 376-9.
73. Nilsson-Ehle I, Nord CE, Ursing B. Ceftriaxone: pharmacokinetics and effect on the intestinal microflora in patients with acute bacterial infections. Scand J Infect Dis 1985; 17: 77-82.
74. Guggenbichler JP, Kofler J, Allerberger F. The influence of thirdgeneration cephalosporins on the aerobic intestinal flora. Infection 1985; 13 Suppl 1: S137-9.
75. de Lastours V, Goulenok T, Guérin F et al. Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in gut microbiota from hospitalized patients. Eur J Clin Microbiol Infect Dis 2018; 37: 417-21.
76. Meletiadis J, Turlej-Rogacka A, Lerner A et al. Amplification of antimicrobial resistance in gut flora of patients treated with ceftriaxone. Antimicrob Agents Chemother 2017; 61: e00473-17.
77. Baggs J, Fridkin SK, Pollack LA et al. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med 2016; 176: 1639-48.
78. Wendt C, Lin D, von Baum H. Risk factors for colonization with thirdgeneration cephalosporin-resistant Enterobacteriaceae. Infection 2005; 33: 327-32.
79. Lambert Zechovsky N, Bingen E, Aujard Y et al. Impact of cefotaxime on the fecal flora in children. Infection 1985; 13 Suppl 1: S140-4.
80. Crew PE, Rhodes NJ, O'Donnell JN et al. Correlation between hospital-level antibiotic consumption and incident health care facilityonset Clostridium difficile infection. Am J Infect Control 2018; 46: 270-5.
81. Slimings C, Riley TV. Antibiotics and hospital-Acquired Clostridium difficile infection: update of systematic review and meta-Analysis. J Antimicrob Chemother 2014; 69: 881-91.
82. McKinnell JA, Kunz DF, Chamot E et al. Association between vancomycinresistant enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol 2012; 33: 718-24.
83. Bergan T, Nord CE, Thorsteinsson SB. Effect of meropenem on the intestinalmicroflora. Eur J ClinMicrobiol Infect Dis 1991; 10: 524-7.
84. Norrby SR, Rogers JD, Ferber F et al. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother 1984; 26: 707-14.
85. Kager L, Brismar B, Malmborg AS et al. Imipenem concentrations in colorectal surgery and impact on the colonic microflora. Antimicrob Agents Chemother 1989; 33: 204-8.
86. Pletz MWR, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.
87. Vardakas KZ, Trigkidis KK, Boukouvala E et al. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-Analysis. Int J Antimicrob Agents 2016; 48: 1-10.
88. Brown KA, Khanafer N, Daneman N et al.Meta-Analysis of antibiotics and the risk of community-Associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57: 2326-32.
89. Van Boeckel TP, Gandra S, Ashok A et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742-50.
90. WiströmJ, Gentry LO, Palmgren AC et al. Ecological effects of short-Term ciprofloxacin treatment of travellers' diarrhoea. J Antimicrob Chemother 1992; 30: 693-706.
91. BorzioM, Salerno F, SaudelliMet al. Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. Ital J Gastroenterol Hepatol 1997; 29: 262-6.
92. Edlund C, Sjöstedt S, Nord CE. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis 1997; 29: 383-6.
93. Inagaki Y, Nakaya R, Chida T et al. The effect of levofloxacin, an opticallyactive isomer of ofloxacin, on fecal microflora in human volunteers. Jpn J Antibiot 1992; 45: 241-52.
94. Edlund C, Beyer G, Hiemer-BauMet al. Comparative effects ofmoxifloxacin and clarithromycin on the normal intestinalmicroflora. Scand J Infect Dis 2000; 32: 81-5.
95. de Lastours V, Fantin B. Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiol 2015; 10: 1241-55.
96. de Lastours V, Chau F, Roy C et al. Emergence of quinolone resistance in themicrobiota of hospitalized patients treated or not with a fluoroquinolone. J Antimicrob Chemother 2014; 69: 3393-400.
97. Nicolas-Chanoine M-H, Bertrand X, Madec J-Y. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27: 543-74.
98. Deshpande A, Pasupuleti V, Thota P et al. Community-Associated Clostridium difficile infection and antibiotics: a meta-Analysis. J Antimicrob Chemother 2013; 68: 1951-61.
99. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
100. Rashid M-U, Weintraub A, Nord CE. Effect of new antimicrobial agents on the ecological balance of humanmicroflora. Anaerobe 2012; 18: 249-53.
101. Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50: 3375-80.
102. Rashid M-U, Rosenborg S, Panagiotidis G et al. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Int J Antimicrob Agents 2015; 46: 60-5.
103. Young VB, Schmidt TM. Antibiotic-Associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004; 42: 1203-6.
104. De La Cochetière MF, Durand T, Lepage P et al. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol 2005; 43: 5588-92.
105. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4554-61.
106. Rashid M-U, Zaura E, Buijs MJ et al. Determining the long-Term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. Clin Infect Dis 2015; 60 Suppl 2: S77-84.
107. Favier CF, Vaughan EE, De VosWMet al.Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol 2002; 68: 219-26.
108. Seksik P, Rigottier-Gois L, Gramet G et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-42.